FY2026 Earnings Estimate for NVO Issued By Erste Group Bank

Novo Nordisk A/S (NYSE:NVO) – Investment analysts at Erste Group Bank lowered their FY2026 earnings per share (EPS) estimates for shares of Novo Nordisk A/S in a research report issued to clients and investors on Wednesday, July 15th. Erste Group Bank analyst H. Engel now anticipates that the company will post earnings per share of $3.22 for the year, down from their previous estimate of $3.23. The consensus estimate for Novo Nordisk A/S’s current full-year earnings is $3.38 per share.

Other research analysts have also recently issued reports about the stock. HSBC reissued a “hold” rating on shares of Novo Nordisk A/S in a research report on Monday, July 6th. Wall Street Zen downgraded shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research note on Saturday, June 20th. Zacks Research lowered shares of Novo Nordisk A/S from a “hold” rating to a “strong sell” rating in a report on Monday. Wolfe Research initiated coverage on shares of Novo Nordisk A/S in a research report on Thursday, March 26th. They issued a “peer perform” rating for the company. Finally, Citigroup restated a “neutral” rating on shares of Novo Nordisk A/S in a research note on Tuesday, May 12th. Five equities research analysts have rated the stock with a Buy rating, sixteen have issued a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, Novo Nordisk A/S currently has an average rating of “Hold” and a consensus target price of $65.56.

Novo Nordisk A/S Stock Up 1.9%

Shares of NYSE:NVO opened at $51.50 on Friday. The company has a market capitalization of $229.96 billion, a price-to-earnings ratio of 12.09, a price-to-earnings-growth ratio of 4.61 and a beta of 0.77. The company has a 50 day moving average of $46.01 and a two-hundred day moving average of $45.79. Novo Nordisk A/S has a 52-week low of $35.12 and a 52-week high of $71.79. The company has a quick ratio of 0.56, a current ratio of 0.79 and a debt-to-equity ratio of 0.59.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings results on Tuesday, March 31st. The company reported $1.03 EPS for the quarter. The firm had revenue of $10.85 billion for the quarter. Novo Nordisk A/S had a return on equity of 63.31% and a net margin of 37.23%.

Hedge Funds Weigh In On Novo Nordisk A/S

Several institutional investors and hedge funds have recently made changes to their positions in NVO. CIBC Bancorp USA Inc. acquired a new stake in shares of Novo Nordisk A/S in the 3rd quarter valued at about $19,519,000. Romano Brothers AND Company increased its holdings in Novo Nordisk A/S by 704.0% in the fourth quarter. Romano Brothers AND Company now owns 34,236 shares of the company’s stock valued at $1,742,000 after buying an additional 29,978 shares during the last quarter. Capital Investment Counsel LLC bought a new stake in Novo Nordisk A/S in the fourth quarter valued at about $3,727,000. Marathon Capital Management raised its stake in Novo Nordisk A/S by 43.9% during the fourth quarter. Marathon Capital Management now owns 82,705 shares of the company’s stock valued at $4,208,000 after buying an additional 25,230 shares in the last quarter. Finally, CWA Asset Management Group LLC raised its stake in Novo Nordisk A/S by 131.9% during the fourth quarter. CWA Asset Management Group LLC now owns 76,993 shares of the company’s stock valued at $3,917,000 after buying an additional 43,793 shares in the last quarter. 11.54% of the stock is currently owned by hedge funds and other institutional investors.

More Novo Nordisk A/S News

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: India approved Wegovy for treatment of metabolic dysfunction-associated steatohepatitis (MASH), opening another potential commercial use for Novo Nordisk’s obesity drug and expanding its addressable market. Article: India approves Novo Nordisk’s obesity drug Wegovy for fatty liver disease
• Positive Sentiment: The European Commission approved an oral Wegovy pill for weight management, making it the first GLP-1 tablet for obesity cleared in the EU and potentially improving convenience, uptake, and Novo’s competitive position versus Eli Lilly. Article: Novo Nordisk wins EU approval for Wegovy weight-loss pill
• Positive Sentiment: News that Eli Lilly’s obesity pill is still trailing Novo’s, even months after launch, reinforces Novo Nordisk’s first-mover advantage in oral obesity treatments. Article: Eli Lilly’s obesity pill is said to trail Novo’s even three months after launch
• Positive Sentiment: Novo also secured European approval for a higher-dose Wegovy single-dose pen, adding another product-format option that could help broaden prescriptions and patient access. Article: Novo wins EU nod for Wegovy pill and higher-dose Wegovy in single-dose pen
• Neutral Sentiment: Brokerages currently rate Novo Nordisk with an average “Hold,” suggesting analysts see upside drivers but also meaningful valuation and competition concerns. Article: Novo Nordisk A/S (NYSE:NVO) Given Average Recommendation of “Hold” by Brokerages
• Neutral Sentiment: Analysts have nudged fair value estimates slightly higher as they revise growth assumptions, but the move is modest and does not materially change the near-term story. Article: Novo Nordisk (CPSE:NOVO B) Stock Fair Value Edges Higher As Analysts Rework Growth Assumptions
• Negative Sentiment: Sun Pharmaceutical’s approval to launch a generic version of semaglutide in South Africa highlights emerging competition to Novo’s diabetes and obesity franchise, which could pressure pricing over time. Article: India’s Sun Pharma wins South Africa approval to launch generic Ozempic

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.